{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:49Z","timestamp":1764510409221},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.leukres.2011.05.010","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T14:22:56Z","timestamp":1308493376000},"page":"e169-e170","source":"Crossref","is-referenced-by-count":12,"title":["Molecular response to first line nilotinib in a patient with e19a2 BCR\u2013ABL1 chronic myeloid leukemia"],"prefix":"10.1016","volume":"35","author":[{"given":"Stephen E.","family":"Langabeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peig","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.05.010_bib0005","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.010_bib0010","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.05.010_bib0015","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.05.010_bib0020","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood.V116.21.3427.3427","article-title":"Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR\u2013ABL RQ-PCR","volume":"116","author":"Conneally","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.010_bib0025","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.05.010_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.leukres.2007.03.001","article-title":"Y253H mutation appearing in a micro-BCR\u2013ABL (e19a2) CML","volume":"32","author":"Popovici","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.010_bib0035","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/j.leukres.2010.03.036","article-title":"A T315I mutation in e19a2 BCR\/ABL1 chronic myeloid leukemia responding to dasatinib","volume":"34","author":"Cea","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.010_bib0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cancergencyto.2010.05.012","article-title":"Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib","volume":"201","author":"Martin","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2011.05.010_bib0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","article-title":"Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"150","author":"Santos","year":"2010","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.leukres.2011.05.010_bib0050","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR\u2013ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T11:00:02Z","timestamp":1592650802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261100227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S014521261100227X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.05.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}